Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis

Nagoya Journal of Medical Science

Volumn 78, Issue 1, 2016, Pages 119-122

  Maeda, Osamu ^a   Yokota, Kenji ^b   Atsuta, Naoki ^b   Katsuno, Masahisa ^b   Akiyama, Masashi ^b   Ando, Yuichi ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti programmed death 1 (PD 1) monoclonal antibody; Creatine phosphokinase; Malignant melanoma; Myasthenia gravis; Nivolumab

Indexed keywords

EID: 84994158163     PISSN: 00277622     EISSN: 21863326     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M, Katoh N, Nishie K, Okuyama R, Uhara H. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol, 2016; 46(1): 86-88.
2. Yoshioka M, Kambe N, Yamamoto Y, Suehiro K, Matsue H. Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol, 2015; 24(10): 1008-1009.
3. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med, 2012; 366(26): 2455-2465.
4. Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol. 2015; 33(33): e122-124.
5. Loochtan AI, Nickolich MS, Hobson-Webb LD. Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve, 2015; 52(2): 307-308.